Abstract

Preview
Heparin-induced thrombocytopenia (HIT) is a drug-induced autoimmune disorder, characterised by thrombocytopenia, an increased incidence of venous, arterial and/or microvascular thrombosis, and auto-antibodies that recognise multimolecular complexes of platelet factor 4 (PF4) bound to heparin or other polyanions1.
Administration of the ChAdOx1 nCoV-19 Astra Zeneca vaccine is frequently followed by flu-like symptoms, such as fatigue, fever, headache, muscle and joint pain, which subside after 1 or 2 days, but in some cases, symptoms can persist beyond the third day. Recently, sinus/cerebral vein thrombosis, pulmonary embolism and splanchnic vein thrombosis, associated with low platelet counts and elevated D-dimer levels, have been reported 5 to 20 days after the first dose of the ChAdOx1 nCoV-19 Astra Zeneca vaccine. This constellation of events has recently been assigned the operative acronym of VITT (vaccine-induced immune thrombotic thrombocytopenia). [ ... ]

Downloads

Authors

Maria Costanza Turi - Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Francesca Spitaleri - Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Anna M. Gori - Department of Experimental and Clinical Medicine, University of Florence, Italy

Giustino Parruti - Infectious Diseases Unit, “Spirito Santo” Hospital, Pescara, Italy

Angela A. Rogolino - Department of Experimental and Clinical Medicine, University of Florence, Italy

Alberto Albani - Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Betti Giusti - Department of Experimental and Clinical Medicine, University of Florence, Italy

Luciano Agostinone - Intensive Care Unit, “Spirito Santo” Hospital, Pescara, Italy

Francesca Cesari - Department of Experimental and Clinical Medicine, University of Florence, Italy

Paola Ranalli - Centre for Haemorrhagic, Thrombotic and Rare Haematological Diseases, “Spirito Santo” Hospital, Pescara, Italy

Stefano Pulini - Haematology Unit, “Spirito Santo” Hospital, Pescara, Italy

Giorgia Di Gioacchino - Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Roberto Paganelli - Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, and YDA, Institute of Clinical Immunotherapy and Advanced Biological Treatments, Pescara, Italy

Rossella Marcucci - Department of Experimental and Clinical Medicine, University of Florence, Italy

  • Abstract viewed - 7 times
  • PDF downloaded - 1 times